This effect is likely attributable to the HDAC‐inhibitory activity of P2 and is consistent with those of previous studies demonstrating that HDAC inhibition can epigenetically upregulate the expression of MHC class I genes.[46, 47] These findings suggest that P2 exerts dual immunomodulatory effects by reactivating innate immunity and promoting tumor antigen presentation, which together may expand its therapeutic potential, particularly in tumors with partial or complete loss of STING expression. This evidence concerns the gene HDAC9 and neoplasm.